Ensysce Biosciences, Inc. (ENSC) Stock Score, Valuation & Financial Research

Ensysce Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ENSC

Ensysce Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.42. These figures are a research snapshot, not a buy or sell recommendation.

What Ensysce Biosciences, Inc. does

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Ensysce Biosciences is a clinical-stage pharmaceutical company that generates no commercial revenue. Its business model relies on research and development of proprietary prodrug technology platforms, specifically TAAP and MPAR, to create abuse-deterrent opioid candidates, funded primarily through equity offerings, debt financing, and potential future licensing or partnership agreements.

Products and services

The company is developing a pipeline of opioid prodrug candidates, including PF614 and PF614-MPAR, designed to be tamper-resistant and reduce the risk of prescription drug abuse.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company relies on various unnamed third-party CROs to conduct clinical trials and manage regulatory processes. Source
Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party CMOs for the manufacturing of its clinical trial drug supplies. Source

Competitors and product-market comparisons

Pharmaceutical companies developing abuse-deterrent opioids — The company competes with various pharmaceutical entities that develop and market pain management therapies, including those with abuse-deterrent formulations. Source

Business strengths to evaluate

Proprietary TAAP and MPAR technology platforms Source

Business risks and research considerations

History of operating losses and dependence on additional financing Source
Clinical trial failure or regulatory rejection Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ENSC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 0.42
Market capitalization:: 6.39M (currency not supplied)
Revenue:: USD 1.16M
Net income:: USD -12.62M
Free cash flow:: USD -7.93M
Cash:: USD 676.7K
Total debt:: USD 196.84K
EPS:: USD -2.76

What stands out

Free cash flow is USD -7.93M, negative for the stored period.
The balance sheet shows USD 676.7K of cash versus USD 196.84K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Free cash flow is -681.1% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
Net income equals -1084.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
Cash exceeds debt by USD 479.86K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ENSC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can ENSC fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is ENSC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for ENSC to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of ENSC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ENSC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.